Document is current
Any future updates will be listed below
-
Authors
Saglio, Giuseppe https://orcid.org/0000-0002-1046-3514
Rosti, Gianantonio
Hehlmann, Rüdiger
Hochhaus, Andreas
Gale, Robert Peter https://orcid.org/0000-0002-9156-1676
-
Funding
Funding for this research was provided by:
DH | National Institute for Health Research
- License Information
-
More Information
Article History
Received: 23 January 2022
Revised: 27 January 2022
Accepted: 3 February 2022
First Online: 28 February 2022
Competing interests
: RPG is a consultant to BeiGene Ltd., Fusion Pharma LLC, La Jolla NanoMedical Inc., Mingsight Pharmaceuticals Inc., CStone Pharmaceuticals, NexImmune Inc., and Prolacta Bioscience; advisor to Antengene Biotech LLC, Medical Director, FFF Enterprises Inc.; partner, AZAC Inc.; Board of Directors, Russian Foundation for Cancer Research Support; and Scientific Advisory Board: StemRad Ltd. The other authors declare no competing interests.
